Initially, the LABXpress system will address the need for high throughput screening of blood samples by blood banks concerned about the presence of antibodies directed towards Human Leukocyte Antigens (HLA) and Human Neutrophil Antigens (HNA) in blood products. Recent research suggests that HLA and HNA antibodies may be contributing factors in Transfusion Related Acute Lung Injury (TRALI), and these tests will allow blood centers to further investigate their role. High volume solid organ and bone marrow transplant centers will also benefit from LABXpress’ hands-free capabilities. HLA laboratory personnel will be able to load samples and LABType or LABScreen reagents and walk away as samples are processed for HLA typing and/or antibody screening, respectively. Upon completion of sample processing, the LABXpress automatically transfers the samples to the fully integrated LABScan™100 flow analyzer utilizing Luminex® xMAP® technology. Finally, the acquired data will be analyzed using One Lambda’s HLA Fusion™ software. Both companies will enter into a development and supply cooperation for a fully automated screening system to meet the demands of high throughput laboratories in this market.
About One Lambda One Lambda Inc. (http://www.onelambda.com) is the world wide leader in HLA typing and antibody detection assays. One Lambda is known for its commitment to quality, service and innovation. One Lambda develops and distributes several lines of histocompatibility (HLA) typing and antibody detection tests utilizing serological, molecular, ELISA, flow, and Luminex xMAP technologies. One Lambda also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations.
About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and on other exchanges. The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG and its subsidiaries STRATEC Biomedical Inc., STRATEC NewGen GmbH, Robion AG and Sanguin International Ltd., as well as Sanguin International Inc., a subsidiary of Sanguin International Ltd.
Further information can be obtained from: One Lambda, Inc. Stewart Han, Director of Marketing 21001 Kittridge Street Canoga Park, CA 91303 Tel: 818-702-0042 Fax: 818-702-6904 E-mail: shan@onelambda.com
STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 7082 7916 190 Fax: +49 7082 7916 999 E-Mail: ir@stratec-biomedical.de
